Abstract |
Introduction: Head and neck squamous cell carcinoma ( HNSCC) is one of the most common cancers worldwide and is a leading cause for cancer-related mortality. This review attempts to give a comprehensive summary of the recent developments in pharmacotherapeutic options for locally advanced/metastatic HNSCC.Areas covered: In this review, the authors conducted a systematic literature search for published articles on HNSCC in the PubMed database using the keywords ' head and neck squamous cell carcinoma or HNSCC,' 'targeted therapy,' ' immunotherapy.' The search was restricted to meta-analyses, clinical trials, practice guidelines, and abstract presentations at international meetings. The final search encompassed articles published from 2010 to 2021. Articles published in languages other than English were excluded.Expert opinion: Immune checkpoint inhibition has been the most significant advance in the treatment of R/M HNSCC. Oral metronomic therapy has emerged as an important therapeutic option for low to middle-income countries. H-RAS inhibition is one of the most promising areas of research.
|
Authors | Shikhar Kumar, Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Menon, Kumar Prabhash |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 22
Issue 15
Pg. 2007-2018
(Oct 2021)
ISSN: 1744-7666 [Electronic] England |
PMID | 34187268
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Head and Neck Neoplasms
(drug therapy)
- Humans
- Immunologic Factors
- Immunotherapy
- Squamous Cell Carcinoma of Head and Neck
(drug therapy)
|